Clinical trials: Adverse Event
Blood Pressure
Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) Trial
The purpose of this study is to compare the blood pressure lowering efficacy of a treatment regimen based on a dihydropyridine calcium-channel blocker combined with an angiotensin II type-1 receptor blocker with the recommended…
- Trial name
- NOAAH (NCT01030458)
- Testing
- amlodipine 5/10 mg per day plus valsartan 160 mg/day, hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day
- Where
- 7 sites in Cameroon, Côte d’Ivoire and 3 more
- Volunteers
- 183 people
- Sponsor
- KU Leuven
CNI Side Effects
Calcineurin Inhibitor Sparing After Kidney Transplantation
Reducing drug side effects is a key issue in transplantation. One class of drugs commonly used, calcineurin inhibitors (CNIs), is associated with negative side effects, namely, toxicity to the transplanted kidney.
- Trial name
- CNI-Sparing (NCT01062555)
- Testing
- Cyclosporine & Cellcept, Prograf & Cellcept, Low Dose CNI (Cyclosporine or FK) and Cellcept
- Where
- United States
- Volunteers
- 527 people
- Sponsor
- University of Minnesota
Ulcerative Colitis
Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).
- Trial name
- NCT05570006
- Testing
- ABBV-668
- Where
- 30 sites in United States, Belgium and 2 more
- Volunteers
- 30 people
- Sponsor
- AbbVie
Contraception
Long-Acting Reversible Contraception
In the proposed study, women aged 18-29 seeking oral or injectable contraception will be offered an opportunity to try LARC instead; the FDA-approved options include two types of intrauterine products and one type of subdermal…
- Trial name
- LARC (NCT01299116)
- Testing
- DMPA, oral contraceptives, Implanon®
- Where
- United States
- Volunteers
- 916 people, healthy volunteers welcome
- Sponsor
- FHI 360
Ventilator Adverse Event, Ventilator Associated Pneumonia
Effect of Angulus on Patient-elevation Compliance
Ventilator-associated events (VAE) are a scourge of critical care settings and hospital systems at large. There is extensive evidence that ventilator-associated pneumonia (VAP) and related VAEs increase mortality rates in…
- Conditions
- Ventilator Adverse Event, Ventilator Associated Pneumonia, Hospital Acquired Condition, Hospital-acquired Pneumonia
- Trial name
- NCT03496220
- Testing
- Angulus
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Angulus, LLC
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries, representing approximately 30% of all adult leukemias.
- Trial name
- NCT05105841
- Testing
- Venetoclax, Ibrutinib, Obinutuzumab
- Where
- 20 sites in Japan
- Volunteers
- 20 people
- Sponsor
- AbbVie
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer
RATIONALE: Pyridoxine (vitamin B6) may prevent or lessen hand-foot syndrome caused by chemotherapy. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer
- Trial name
- NCT00245050
- Testing
- pyridoxine hydrochloride, doxorubicin HCL liposome
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Acromegaly, Neuroendocrine Tumors
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
This is a Phase II, open-label multicentre, randomised study to assess the PK, PD, efficacy, and safety of two dosing regimens of CAM2029 in adult patients with acromegaly or a functional, well-differentiated NET, with carcinoid…
- Trial name
- NCT02299089
- Testing
- octreotide FluidCrystal® injection depot
- Where
- 10 sites in France, Germany and 2 more
- Volunteers
- 12 people
- Sponsor
- Camurus AB
Type 1 Diabetes Mellitus
Fast Track CSII Using a Novel Device in Young Children With Newly Diagnosed T1DM
This study evaluates early initiation of continuous subcutaneous insulin infusion (CSII) therapy in young children using a novel delivery method in the form of a self-contained, lightweight, and disposable insulin pump unit…
- Trial name
- NCT00476788
- Testing
- Omnipod Insulin Management System
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Postoperative Wound Infection
Study of the Efficacy of Plain Soap and Water Versus Alcohol-based Rubs for Surgical Hand Preparation
Surgical site infections (SSI) constitute a significant health-economic and clinical challenge. The investigators conducted a cluster-randomized, cross-over study to compare the efficacy of plain soap and water (PSW), used…
- Trial name
- NCT00987402
- Testing
- Plain soap and water (PSW), Alcohol-based hand rub (ABHR)
- Where
- Kenya
- Volunteers
- 3,317 people
- Sponsor
- University Hospital, Geneva
Cystic Fibrosis (CF)
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis
Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects the lungs and digestive system, significantly impairing the quality of life, with those affected having a median age of death at 40.
- Trial name
- NCT04853368
- Testing
- ABBV-576, Galicaftor, Navocaftor
- Where
- 41 sites in United States, Australia and 5 more
- Volunteers
- 48 people
- Sponsor
- AbbVie